Annual Revenue
$60.28 M
+$33.13 M+122.05%
31 December 2023
Summary:
Adaptimmune Therapeutics annual revenue is currently $60.28 million, with the most recent change of +$33.13 million (+122.05%) on 31 December 2023. During the last 3 years, it has risen by +$56.32 million (+1423.02%). ADAP annual revenue is now -67.69% below its all-time high of $186.56 million, reached on 01 December 2013.ADAP Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$40.90 M
-$87.33 M-68.10%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly revenue is currently $40.90 million, with the most recent change of -$87.33 million (-68.10%) on 30 September 2024. Over the past year, it has increased by +$33.58 million (+458.83%). ADAP quarterly revenue is now -68.10% below its all-time high of $128.23 million, reached on 30 June 2024.ADAP Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$175.04 M
+$33.58 M+23.74%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM revenue is currently $175.04 million, with the most recent change of +$33.58 million (+23.74%) on 30 September 2024. Over the past year, it has increased by +$103.96 million (+146.27%). ADAP TTM revenue is now at all-time high.ADAP TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +122.0% | +458.8% | +146.3% |
| 3 y3 years | +1423.0% | +3299.9% | +2707.8% |
| 5 y5 years | +1.3% | +10000.0% | +9245.5% |
ADAP Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +1423.0% | -68.1% | >+9999.0% | at high | +2746.7% |
| 5 y | 5 years | at high | +5272.6% | -68.1% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | -67.7% | +7206.8% | -68.1% | >+9999.0% | at high | >+9999.0% |
Adaptimmune Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $40.90 M(-68.1%) | $175.04 M(+23.7%) |
| June 2024 | - | $128.23 M(+2158.4%) | $141.46 M(+670.6%) |
| Mar 2024 | - | $5.68 M(+2358.0%) | $18.36 M(-69.5%) |
| Dec 2023 | $60.28 M(+122.0%) | $231.00 K(-96.8%) | $60.28 M(-15.2%) |
| Sept 2023 | - | $7.32 M(+42.7%) | $71.08 M(+0.4%) |
| June 2023 | - | $5.13 M(-89.2%) | $70.77 M(-0.6%) |
| Mar 2023 | - | $47.60 M(+331.6%) | $71.17 M(+162.2%) |
| Dec 2022 | $27.15 M(+341.5%) | $11.03 M(+57.4%) | $27.15 M(+54.8%) |
| Sept 2022 | - | $7.01 M(+26.5%) | $17.54 M(+49.5%) |
| June 2022 | - | $5.54 M(+54.9%) | $11.73 M(+26.3%) |
| Mar 2022 | - | $3.58 M(+152.3%) | $9.29 M(+51.1%) |
| Dec 2021 | $6.15 M(+55.4%) | $1.42 M(+17.8%) | $6.15 M(-1.4%) |
| Sept 2021 | - | $1.20 M(-61.1%) | $6.23 M(+0.2%) |
| June 2021 | - | $3.10 M(+613.1%) | $6.22 M(+71.4%) |
| Mar 2021 | - | $434.00 K(-71.1%) | $3.63 M(-8.3%) |
| Dec 2020 | $3.96 M(+252.8%) | $1.50 M(+25.9%) | $3.96 M(+24.3%) |
| Sept 2020 | - | $1.19 M(+137.6%) | $3.18 M(+42.9%) |
| June 2020 | - | $502.00 K(-34.0%) | $2.23 M(+18.3%) |
| Mar 2020 | - | $761.00 K(+4.5%) | $1.88 M(+67.8%) |
| Dec 2019 | $1.12 M | $728.00 K(+207.2%) | $1.12 M(-40.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $237.00 K(+51.0%) | $1.87 M(-95.6%) |
| June 2019 | - | $157.00 K(-89.4%) | $42.43 M(-28.7%) |
| Dec 2018 | $59.51 M(+57.3%) | $1.48 M(-96.4%) | $59.51 M(-4.5%) |
| Sept 2018 | - | $40.79 M(+351.3%) | $62.30 M(+27.9%) |
| June 2018 | - | $9.04 M(+10.3%) | $48.69 M(+12.8%) |
| Mar 2018 | - | $8.20 M(+91.9%) | $43.17 M(+14.1%) |
| Dec 2017 | $37.83 M(+166.5%) | $4.27 M(-84.3%) | $37.83 M(-10.1%) |
| Sept 2017 | - | $27.18 M(+672.1%) | $42.10 M(+142.9%) |
| June 2017 | - | $3.52 M(+23.2%) | $17.33 M(+22.6%) |
| Mar 2017 | - | $2.86 M(-66.5%) | $14.14 M(-0.4%) |
| Dec 2016 | $14.20 M(+58.1%) | $8.54 M(+253.3%) | $14.20 M(+150.8%) |
| Sept 2016 | - | $2.42 M(+636.6%) | $5.66 M(-21.2%) |
| June 2016 | - | $328.00 K(-88.8%) | $7.19 M(+4.8%) |
| Mar 2016 | - | $2.92 M(-25.9%) | $6.86 M(+10.5%) |
| Dec 2015 | $8.98 M(-9.0%) | - | - |
| Sept 2015 | - | $3.94 M(+73.7%) | $6.21 M(+63.3%) |
| June 2015 | $9.87 M(+1096.5%) | - | - |
| Dec 2014 | - | $2.27 M(+47.9%) | $3.80 M(+147.9%) |
| Sept 2014 | - | $1.53 M | $1.53 M |
| June 2014 | $825.00 K(-99.6%) | - | - |
| Dec 2013 | $186.56 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual revenue?
- What is the all time high annual revenue for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual revenue year-on-year change?
- What is Adaptimmune Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly revenue year-on-year change?
- What is Adaptimmune Therapeutics TTM revenue?
- What is the all time high TTM revenue for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM revenue year-on-year change?
What is Adaptimmune Therapeutics annual revenue?
The current annual revenue of ADAP is $60.28 M
What is the all time high annual revenue for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual revenue is $186.56 M
What is Adaptimmune Therapeutics annual revenue year-on-year change?
Over the past year, ADAP annual revenue has changed by +$33.13 M (+122.05%)
What is Adaptimmune Therapeutics quarterly revenue?
The current quarterly revenue of ADAP is $40.90 M
What is the all time high quarterly revenue for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly revenue is $128.23 M
What is Adaptimmune Therapeutics quarterly revenue year-on-year change?
Over the past year, ADAP quarterly revenue has changed by +$33.58 M (+458.83%)
What is Adaptimmune Therapeutics TTM revenue?
The current TTM revenue of ADAP is $175.04 M
What is the all time high TTM revenue for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM revenue is $175.04 M
What is Adaptimmune Therapeutics TTM revenue year-on-year change?
Over the past year, ADAP TTM revenue has changed by +$103.96 M (+146.27%)